Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
California Appellate Court Affirms Enforceability of Federal Forum Provisions in Securities Act LitigationDecember 17, 2025Sidley Represents Fortidia in Strategic Partnership With BC PartnersDecember 17, 2025Sidley Represents ABM In Its US$275 Million Acquisition of WGNSTARDecember 17, 2025Sidley Represents FMR LLC, in Obtaining OCC Approval for “Fidelity Digital Assets, National Association”December 15, 2025Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory